Compare CCCC & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | OPRX |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 261.5M |
| IPO Year | 2020 | N/A |
| Metric | CCCC | OPRX |
|---|---|---|
| Price | $2.50 | $13.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $8.50 | ★ $14.83 |
| AVG Volume (30 Days) | ★ 1.4M | 226.0K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | $30,108,000.00 | ★ $109,506,000.00 |
| Revenue This Year | N/A | $19.77 |
| Revenue Next Year | N/A | $11.33 |
| P/E Ratio | ★ N/A | $7,324.68 |
| Revenue Growth | N/A | ★ 24.18 |
| 52 Week Low | $1.09 | $3.99 |
| 52 Week High | $4.70 | $22.25 |
| Indicator | CCCC | OPRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 34.62 |
| Support Level | $2.50 | $13.14 |
| Resistance Level | $2.69 | $14.95 |
| Average True Range (ATR) | 0.18 | 0.66 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 23.86 | 14.05 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.